How does GILD's PS Ratio compare to its peers?

GILD is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (6.8x).

How does GILD's PS Ratio compare vs other companies in the Global Biotechs Industry?

GILD is good value based on its Price-To-Sales Ratio (3.9x) compared to the Global Biotechs industry average (9.3x).

What is GILD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate GILD's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of GILD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

GILD ($89.71) is trading below our estimate of [[fair value]] ($199.2)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Gilead Sciences (SNSE:GILD) - Stock Price, News & Analysis

GILD Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

GILD fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 55% below our estimate of its fair value

Earnings are forecast to grow 40.94% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the CL market

Has a high level of debt

Large one-off items impacting financial results

Profit margins (0.4%) are lower than last year (21.5%)

+ 1 more risk

Gilead Sciences, Inc. Competitors

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$116.2b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$80.0b

Amgen

NasdaqGS:AMGN

US$154.7b

CSL

ASX:CSL

AU$132.5b

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share Price	US$89.71
52 Week High	US$89.71
52 Week Low	US$79.49
Beta	0.19
11 Month Change	12.86%
3 Month Change	36.86%
1 Year Change	36.86%
33 Year Change	36.86%
5 Year Change	34.00%
Change since IPO	18.51%

Recent updates

Shareholder Returns

	GILD	CL Biotechs	CL Market
7D	0%	0%	0%
1Y	36.9%	0%	0%

Return vs Industry: GILD exceeded the CL Biotechs industry which returned 8.9% over the past year.

Return vs Market: GILD exceeded the CL Market which returned 10.5% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement	7.1%
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in CL Market	0%
10% least volatile stocks in CL Market	0%

Stable Share Price: GILD's share price has been volatile over the past 3 months compared to the CL market.

Volatility Over Time: GILD's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CL stocks.

About the Company

Founded	Employees	CEO	Website
1987	18,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market cap	US$110.34b
Earnings (TTM)	US$126.00m
Revenue (TTM)	US$28.30b

875.7x

P/E Ratio

3.9x

P/S Ratio

Is GILD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GILD income statement (TTM)
Revenue	US$28.30b
Cost of Revenue	US$6.28b
Gross Profit	US$22.02b
Other Expenses	US$21.89b
Earnings	US$126.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.10
Gross Margin	77.80%
Net Profit Margin	0.45%
Debt/Equity Ratio	126.4%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

3,027%

Payout Ratio

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks

When do you need to buy GILD by to receive an upcoming dividend?
Gilead Sciences dividend dates
Ex Dividend Date	Dec 13 2024
Dividend Pay Date	Dec 30 2024
Days until Ex dividend	21 days
Days until Dividend pay date	38 days

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks

GILD Stock Overview

Rewards

Risk Analysis

Gilead Sciences, Inc. Competitors

NasdaqGS:VRTX

US$116.2b

NasdaqGS:REGN

US$80.0b

NasdaqGS:AMGN

US$154.7b

ASX:CSL

AU$132.5b

Price History & Performance

Recent News & Updates

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Third quarter dividend of US$0.77 announced

Third quarter 2024 earnings released: EPS: US$1.01 (vs US$1.75 in 3Q 2023)

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Recent updates

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Third quarter dividend of US$0.77 announced

Third quarter 2024 earnings released: EPS: US$1.01 (vs US$1.75 in 3Q 2023)

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Upcoming dividend of US$0.77 per share

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023)

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

New minor risk - Profit margin trend

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Upcoming dividend of US$0.77 per share

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend increased to US$0.77

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Shareholder Returns

Price Volatility

About the Company

Gilead Sciences, Inc. Fundamentals Summary

875.7x

3.9x

Earnings & Revenue

Dividends

3.5%

3,027%